Ms. Claire Chin is a strategic leader at the intersection of life sciences investment and AI with over 15 years of cross-sector expertise spanning clinical medicine, strategic consulting, venture capital, and artificial intelligence. As Chief Industrial Advisor and Chief Strategy Officer at INTELLIGEN AI, she spearheads biomedical LLM ecosystem development. Holding an MBA from Kellogg School of Management and a clinical medicine dual degree from Shanghai Jiao Tong University, she uniquely bridges deep healthcare and business domains. As former Managing Director at Alibaba Health, head of investment in biopharma, her track record includes leading a $70M+ life science portfolio and securing Asia’s largest AI drug licensing deal ($1.3B per asset). She now pioneers collaborative AI innovation across 30+ institutions to transform drug discovery and precision medicine.
秦祯女士是生命科技投资与人工智能交叉领域的战略领袖，拥有逾15年横跨临床医疗、战略咨询、风险投资及AI产业的跨领域经验。现任INTELLIGEN AI首席产业顾问兼首席战略官，主导生物大语言模型生态建设。她拥有西北大学凯洛格商学院MBA及上海交通大学临床医学本硕学位，兼具顶尖医疗专业与商业战略双重背景。曾任阿里健康董事总经理兼创新药投资负责人，主导了超7000万美元的投资，并推动被投企业达成亚洲最大AI药物授权交易（单项目13亿美元）。目前致力于构建30余家机构的AI协同创新网络，加速药物研发与精准医疗突破。